Menopausal hormone treatment (MHT) might indirectly help with weight loss by improving sleep and redistributing abdominal fat ...

The lawsuit said the union’s health plan allowed coverage of Xenical to treat obesity but not newer products such as Wegovy ...

Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...

Weight-loss injections using GLP-1 receptor agonists mimic a natural hormone in the body that suppresses appetite, slows digestion, and promotes a lasting feeling of fullness.

GLP-1 drugs like semaglutide (Ozempic) and tirzepatide (Mounjaro) may shrink fat, but also crucial muscle mass, with little ...

A recipient of the 2025 Elite Trial Lawyers Lifetime Achievement Award, Morgan & Morgan's John Yanchunis spoke with the National Law Journal about his storied career, from bringing one of the nation’s ...

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

Democrats aren't rushing to play ball with Republicans on a bipartisan health care package after passage of the president's ...

Connecticut passed a new law last week in an effort to lower its spending on weight-loss drugs for its state insurance program — HUSKY Health, which includes Medicaid and CHIP enrollees — and it could ...

Some health experts view GLP-1s as a promising option for PCOS, which lacks a standard treatment and affects millions of ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Explore "The Ozempic Revolution" by Dr Alexandra Sowa—a guide to weight-loss drugs like Ozempic, their benefits, side effects ...